Veru Sells ENTADFI® Business for $20 Million Plus up to an Additional $80 Million…
<!-- Name:DistributionId Value:8811683 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Nasdaq:VERU
Veru Provides FDA Update on Request for Emergency Use Authorization for Sabizabulin…
<!-- Name:DistributionId Value:8780823 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Veru Announces FDA has Updated the Meeting Date for the Advisory Committee Meeting to…
MIAMI, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related…
Veru Announces Date for FDA Advisory Committee Meeting to Review Emergency Use…
MIAMI, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related…
Veru Announces Appointment of Jason Davies to Lead EMEA, LATAM and APAC Infectious…
MIAMI, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases…
European Medicines Agency’s Emergency Task Force Has Initiated the Review of…
MIAMI, July 27, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases…
Veru Submits Emergency Use Authorization (EUA) Application to U.S. FDA for…
-- The EUA Submission Follows Positive Phase 3 COVID-19 Clinical Trial in which Sabizabulin Demonstrated a 55.2% Reduction in Death in Hospitalized COVID-19 Patients -- -- The Company is…
Veru Announces Presentation of Final Positive Phase 1b/2 Clinical Trial Results for…
MIAMI, June 06, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases…
Veru Announces Acceptance of Two Abstracts for Presentation at the 39th Miami Breast…
MIAMI, March 04, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and…
Veru to Present at the Oppenheimer 32nd Annual Healthcare Conference on March 15-17,…
MIAMI, March 01, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and…